Table 4 Time to index DMT discontinuation: cox proportional hazard models for experienced and naïve DMT users
Experienced DMT Users | Naïve DMT Users | |||
|---|---|---|---|---|
Hazard ratio | 95% Confidence interval | Hazard ratio | 95% Confidence interval | |
DMT initiated | ||||
Fingolimod | Reference | Reference | ||
Interferon beta-1b | 2.83 | (1.62-4.93) | 1.90 | (1.25-2.89) |
Intramuscular interferon beta-1a | 2.43 | (1.49-3.97) | 1.53 | (1.03-2.28) |
Subcutaneous interferon beta-1a | 2.42 | (1.54-3.82) | 1.58 | (1.05-2.38) |
Glatiramer acetate | 1.73 | (1.11-2.69) | 1.53 | (1.04-2.24) |
Gender | ||||
Male | Reference | Reference | ||
Female | 1.45 | (0.99-2.11) | 1.07 | (0.89-1.29) |
Age categories | ||||
18-44 | Reference | Reference | ||
45-54 | 0.78 | (0.55-1.11) | 0.81 | (0.68-0.98) |
55-64 | 0.97 | (0.65-1.46) | 0.75 | (0.60-0.94) |
65+ | 0.80 | (0.38-1.69) | 0.67 | (0.44-1.01) |
Region | ||||
West | Reference | Reference | ||
Northeast | 0.68 | (0.40-1.15) | 0.78 | (0.60-1.01) |
Midwest | 0.99 | (0.62-1.59) | 0.88 | (0.69-1.13) |
South | 1.19 | (0.75 -1.87) | 0.88 | (0.69-1.12) |
Prior authorization for index prescription | 1.21 | (0.88-1.65) | 1.25 | (1.06-1.48) |
Copayment for index prescription | ||||
0-<30 | Reference | Reference | ||
30-100 | 0.93 | (0.65-1.32) | 0.95 | (0.78-1.15) |
100+ | 0.92 | (0.59-1.45) | 0.88 | (0.70-1.09) |
Mail order for index prescription | 1.10 | (0.59-2.07) | 0.57 | (0.42-0.78) |
Pharmacy type for index prescription | ||||
Retail | Reference | Reference | ||
Accredo | 1.03 | (0.54 -1.97) | 1.05 | (0.77-1.43) |
Other specialty pharmacy | 1.69 | (0.86-3.31) | 0.78 | (0.56-1.07) |